How long has praluent been on the market?

Praluent (alirocumab) was granted U.S. FDA approval in June 2015 as the first monoclonal‑antibody therapy specifically indicated for lowering low‑density lipoprotein (LDL) cholesterol in patients who need additional LDL‑lowering beyond lifestyle changes and statins.

So, from its launch in mid‑2015 to today (2026) Praluent has been available for about 11 years. The drug has since been adopted in many treatment guidelines and is routinely prescribed for high‑risk cardiovascular patients who cannot reach LDL targets with statins alone.